<DOC>
	<DOCNO>NCT01346150</DOCNO>
	<brief_summary>People Primary Immune Deficiency ( PID ) may develop severe , life-threatening infection result inherit defect gene normally instruct blood-forming cell develop fight infection . PID diseases include Severe Combined Immune Deficiency ( SCID ) , leaky SCID , Omenn syndrome ( OS ) , Reticular Dysgenesis ( RD ) . PIDs may treat transplantation bone marrow stem cell healthy person , case , enzyme replacement gene therapy . Patients SCID among first receive bone marrow stem cell ( also call hematopoietic cell ) transplantation ( HCT ) 40 year ago , HCT standard treatment today group diseases . Since PID disease rare , enough patient single center determine full range cause , natural history , best method treatment . For research study many PID center across North America organize Primary Immune Deficiency Treatment Consortium ( PIDTC ) pool experience study PIDs together . Researchers collect information general health , psychological developmental health , current status immune system help good define future approach PID treatment .</brief_summary>
	<brief_title>Patients Treated SCID ( 1968-2010 )</brief_title>
	<detailed_description />
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<criteria>Investigators institution participate consortium submit data PIDTC Review Panel determine eligibility stratum assignment . The eligibility patient stratification SCID variant treatment employ SCID follow . Strata A , B , C ( Part 1 Retrospective Study ) . Patients eligible retrospective analysis include patient diagnosed SCID treat institution participate consortium 1968 December 31 , 2010 , already enrol PIDTC Protocol 1 . Subjects receive HCT/GT/ERT prior December 31 , 2010 eligible retrospective study . The enrollment criterion subject die prior definitive therapy Strata A , B C. Stratum A , Typical SCID . Patients meet follow inclusion criterion receive HCT eligible enrollment Stratum A ( Classic SCID ) study : Absence low number T cell ( CD3 T cell &lt; 300/microliter ) , low T cell function ( &lt; 10 % low limit normal ) measure response phytohemagglutinin ( PHA ) T cell maternal origin present , &lt; 10 % normal T cell function ( measure response PHA ) . Stratum B , Leaky SCID , Omenn Syndrome , Reticular Dysgenesis . Patients meet follow criterion eligible enrollment Stratum B study : Leaky SCID Reduced number CD3 T cell age 2 year ≥ 300 &lt; 1000/microliter ; &gt; 2 year 4 year ≥ 300 &lt; 800/microliter ; &gt; 4 year ≥ 300 &lt; 600/microliter Absence maternal engraftment ≥ 10 % ≤ 30 % low limit normal T cell function ( measure response PHA ) Omenn Syndrome ( OS ) Generalized skin rash Absence maternal engraftment Detectable CD3 T cell , ≥ 300/microliter Absent low ( 30 % normal ) T cell proliferation antigens patient expose If proliferation antigen perform , least 4 follow 9 supportive criterion , least one must among marked asterisk ( * ) present , patient eligible : Hepatomegaly ; Splenomegaly ; Lymphadenopathy ; Elevated IgE ; Elevated absolute eosinophil count ; *Oligoclonal T cell measure CDR3 length flow cytometry &gt; 80 % CD4+ T cell CD45RO+ ; *Proliferation PHA reduce &lt; 30 % low limit normal SI &lt; 20 ; *Proliferative response mixed leukocyte reaction reduce &lt; 30 % low limit normal Stimulation Index ( SI ) &lt; 5 Reticular Dysgenesis ( RD ) Absence low number T cell ( CD3 T cell &lt; 300/microliter ) No low ( &lt; 10 % low limit normal ) T cell function ( measure response phytohemagglutinin ( PHA ) Severe congenital neutropenia ( absolute neutrophil count &lt; 200/microliter ) Sensorineural deafness and/or absence granulopoiesis bone marrow examination Stratum C , SCID NonHCT Treatments . Patients meet follow criterion treat PEGADA gene therapy autologous modify cell eligible enrollment Stratum C ( SCID nonHCT treatment ) study . ADA Deficient SCID treat PEGADA Any SCID treat gene therapy Strata A , B , C ( Part 2 CrossSectional Study ) Patient inclusion criterion cross sectional study : Eligibility Strata A , B C retrospective study except patient crosssectional study currently survive least 2 year post recent class therapy . Parts 1 2 Retrospective CrossSectional Studies Lack appropriate testing rule HIV infection 1997 ( p24 antigen sensitive ) cause secondary immunodeficiency Presence DiGeorge syndrome Most patient PIDs nucleoside phosphorylase deficiency , ZAP70 deficiency , CD40 ligand deficiency , NEMO deficiency , XLP , cartilage hair hypoplasia ataxia telangiectasia meet inclusion criterion Stratum A , B , C . However , patient one may meet inclusion criterion Stratum B include . MHC Class I MHC Class II antigen deficiency exclude Metabolic condition imitate SCID related disorder folate transporter deficiency , severe zinc deficiency , transcobalamin deficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>